Order-of-magnitude gap: the company is already serving a demand source whose scale dwarfs its own current business
The model's full reasoning — Q3 2017 call → NOWe need to determine if management describes a mismatch of scale between the company and the demand it is already serving. The key is: is the company already inside a large flow of activity, and does management explicitly draw the size contrast, treating it as central? Looking at the transcript: The company is PTC, a software company. They discuss IoT, ThingWorx, etc. They mention a large partner ecosystem, but do they describe being inside something enormous relative to their size? They talk about IoT market growth, but that's generic. They mention "ThingWorx Studio has been generating incredible customer interest... trial program now has over 3,000 enterprises test driving" - that's a specific number but not necessarily enormous relative to company size. They talk about customer expansions, but no explicit contrast like "we have only captured a tiny fraction of the available spend." They mention "our IoT business to achieve bookings growth above the 30% to 40% range" but that's growth, not scale mismatch. They discuss Japan issues, but that's not about scale. They talk about subscription conversion, but that's about business model. No where do they say something like "we are serving only a small fraction of a massive installed base" or "one customer's potential is several times our size." They mention "ThingWorx Navigate" but not with a size contrast. The question asks: does management convey that the company is currently supplying, serving, or participating in something whose size is enormous relative to the company's own business? They mention "over 3,000 enterprises" for trial, but that's not necessarily enormous. They don't say "we have only captured 1% of the market" or similar. They talk about "partner ecosystem" but not with a scale contrast. Thus, answer NO. The transcript does not contain such a description. Management focuses on execution issues, subscription transition, and growth, but not on a mismatch of scale where they are a small player inside a huge flow. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| GDRX | GoodRx Holdings, Inc. | Q2 2022 | 2022-08-08 | F |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| IRTC | iRhythm Technologies, Inc. | Q1 2022 | 2022-05-07 | C+ |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| RELY | Remitly Global, Inc. | Q4 2021 | 2022-03-02 | B |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
HROW · Q4 2021 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...YES The transcript shows management describing Harrow as already inside the large cataract surgery market (4.5–6 million procedures annually) with real, present-tense participation: thousands of customer relationships, shipping north of two million sterile ophthalmic units last year, and touching roughly one million cataract surgeries. They explicitly contrast this scale against 2021 revenues of $72.5 million, noting that even a modest share of the pass-through-eligible market (1 million procedures × premium pricing) would produce “a big number” and drive revenues “more than double” in the near term. They treat the current business as only the “earliest sliver” of what they are already positioned inside, with the binding question being how much of the existing flow they can capture rather than whether the flow exists. This meets both criteria. The answer is YES. The transcript shows management describing Harrow as already inside the large cataract surgery market (4.
WRBY · Q1 2024 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...YES The transcript explicitly states that the company is already inside the optical industry with real business (245 stores serving customers, 83% of stores offering exams, 2.36 million active customers, and growing revenue from glasses, contacts, and exams). Management then draws the size contrast directly, noting that even the longer 900-store target "would still represent a small fraction of the 45,000 optical shops in the U.S." and that over 50% of major metro areas have only one store.
HSTM · Q3 2017 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...**YES** Management describes the company already being inside a much larger flow of activity (the 80 million-person healthcare workforce, of which 4.6 million are in post-acute settings) and explicitly treats the scale mismatch as the central point. They note their strong sales team is already a “steady contributor” to 4.